Skip to content
DataLookout
Menu

NCT07470489

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Jan 31, 2027 to Oct 29, 2026
    • Site details revised
  2. Notable Start date: Sep 30, 2026 to Jan 31, 2027
    • Eligibility criteria expanded, about 69 words
    • Study description expanded, about 11 words
  3. Minor Study title shortened, about 9 wordsv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year

Arms and interventions

Treatment with Zanzalintinib + CemiplimabExperimental

Participants will be treated in 21-day cycles with zanzalintinib 60 mg po daily from days 1-21 and cemiplimab 350 mg IV on day 1 of each cycle. Patients will be treated for a maximum of 24 cycles.

Drugs: Cemiplimab, Zanzalintinib

Sites

1 site in 1 country

  • MD Anderson Cancer CenterHouston, Texas, United States